La cadena de opciones muestra datos clave de las opciones de acciones de CASI Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CASI Pharmaceuticals..

CASI Pharmaceuticals (NASDAQ:CASI) Bolsa, Cadena de Opciones

CASI Pharmaceuticals

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals Inc

Casino Guichard-Perrachon SA

CASINO GUICHARD PERRACHON by Casino Guichard Perrachon SA

Casino Guichard-Perrachon SA ADR

CASIO COMPUTER CO LTD by Casio Computer Co., Ltd.

Casio Computer Co Ltd

CASIO COMPUTER UNSP/ADR by Casio Computer Co., Ltd.

Novartis expands U.S. radiopharma production amid rising competition

CASI Pharmaceuticals (CASI) has released an update. CASI Pharmaceuticals has restructured its senior management to better align with its strategic ...

CASI Pharmaceuticals Revamps Management Structure

CASI Pharmaceuticals (CASI) announced that the Center for Drug Evaluation of China's National Medical Products Administration has approved the Comp...

Casi Pharmaceuticals receives CTA approval from China NMPA for CID-103

CASI Pharmaceuticals Q3 Earnings Preview

Here's the major earnings before the open tomorrow

CASI Pharmaceuticals reports Q3 results

CASI Pharmaceuticals (CASI) has released an update. CASI Pharmaceuticals reported a 12% decrease in third-quarter revenue in 2024 compared to the p...

CASI Pharmaceuticals' Mixed Third-Quarter Performance in 2024

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Shares of Domino's Pizza (DPZ) w...

Berkshire reveals stake in Domino's, Alibaba reports mixed Q2: Morning Buzz

CASI Pharmaceuticals ( ($CASI) ) has issued an update. CASI Pharmaceuticals has received a Termination Process Letter from Acrotech Biopharma regar...

CASI Pharmaceuticals Faces Evomela® License Termination Dispute

17:39 EST Casi Pharmaceuticals (CASI) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movi...

Casi Pharmaceuticals files $200M mixed securities shelf

AFMD

ALHC

AMAT

AMZN

ASTS

ATNM

AZUL

BABA

BILI

BLUE

BTAI

CASI

CATX

CLRB

CRIS

CVSI

DESP

DTEGY

EONGY

HALO

ITRM

KEYUF

KNTNF

LNTH

LUNR

MKGAF

NICE

NLCP

NTES

NVSEF

OCUL

ONEW

PAVM

PDSB

POLA

PVCT

QBTS

RCAT

SACH

SEDG

SIEGY

SLGL

SPCB

SSNLF

TRUG

TWLO

VEON

VISL

WKHS

XNET

Press Releases

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Small Cap

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Ligand Reports Second Quarter 2024 Financial Results

Earnings

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

News

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

AGEN

AMGN

LGND

MRNS

OVID

PIRS

TVTX

VKTX

VRNA

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics

Aileron Therapeutics, Inc. - Common Stock

Aileron Therapeutics

BioVie

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Celularity

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

CEL-SCI

Elevation Oncology

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Fortress Biotech

Gain Therapeutics

IO Biotech

Kezar Life Sciences

OncoCyte

OKYO Pharma

Omega Therapeutics

Passage Bio

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Q32 Bio

Rallybio

Serina Therapeutics

Shattuck Labs

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Xilio Therapeutics

HC Wainwright & Co.

BTIG

Comments

CASI Pharmaceuticals

CASI Pharmaceuticals (CASI) Opciones

CASI Pharmaceuticals (NASDAQ:CASI) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL